AstraZeneca has shed more than £20 billion in market capitalization after disclosing that its experimental heart disease treatment, Wainua, failed to meet its primary clinical endpoint.
The negative data from the late-stage trial triggered a sharp sell-off in the FTSE 100 pharmaceuticals heavyweight, with shares plunging as much as 11% in London trading on Thursday.
This development follows earlier reports that AstraZeneca shares had already tumbled nearly 9% in European trading after the initial disclosure of the trial's shortcomings.
The collapse in valuation underscores the high stakes attached to Wainua, which was viewed as a potential blockbuster in the crowded cardiovascular therapeutics market.
Investors had priced in significant future revenue from the drug, making the failure to demonstrate a reduction in heart disease-related deaths a material disappointment for the company’s growth narrative.
This development follows earlier reports that AstraZeneca shares had already tumbled nearly 9% in European trading after the initial disclosure of the trial's shortcomings.
The sustained selling pressure indicates that the market is reassessing the company's near-term outlook and the robustness of its pipeline beyond its core oncology and respiratory franchises.